<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2369">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130320</url>
  </required_header>
  <id_info>
    <org_study_id>RHM MED1777</org_study_id>
    <nct_id>NCT05130320</nct_id>
  </id_info>
  <brief_title>Severe Asthma Covid Vaccine Response Study</brief_title>
  <acronym>SHINE</acronym>
  <official_title>SHINE: Severe Asthma Covid Vaccine Response Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asthma Allergy &amp; Inflammation Research Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Southampton NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to employ a simple finger-prick home test to detect post vaccination antibody&#xD;
      levels. The investigators will compare antibody responses in patients with severe asthma on&#xD;
      varying treatment regimes (biologics, daily steroids, inhalers-only) with healthy,&#xD;
      age-matched controls to study if the magnitude and range of responses vary between severe&#xD;
      asthmatics and healthy individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SARS-CoV-2 and the resulting COVID-19 pandemic has had a major impact on quality of life in&#xD;
      people with severe asthma. Careful isolation and lockdown measures have protected many&#xD;
      patients, but with major impacts on wellbeing and mental health. Vaccination opens a &quot;light&#xD;
      at the end of the tunnel&quot; by protecting against COVID-19. However, the following questions&#xD;
      remain unanswered for Covid vaccination in severe asthma: 1) What are patients'&#xD;
      expectations/attitudes towards vaccination? 2) Will vaccines induce good immune responses&#xD;
      which protect from Covid-19 infections? The first question is being addressed by a survey&#xD;
      created SHARP, a European Clinical Research Collaboration on severe asthma- people with&#xD;
      asthma from the UK and Europe will be invited to complete the survey. To complement this, the&#xD;
      investigators propose a UK pilot study (carried out in up to four severe asthma centres) to&#xD;
      measure immune responses following vaccination in 200 people with severe asthma. The&#xD;
      investigators will invite 120 people receiving asthma biologics (monoclonal antibodies), 40&#xD;
      people receiving asthma inhalers, 40 people needing daily steroid tablets to control their&#xD;
      asthma, and 50 age-matched healthy people. Immune responses will be studied using a simple&#xD;
      home blood antibody test posted to participants. By pricking their finger, patients will&#xD;
      collect 5-6 drops of blood in a small test tube and will post back on the same day to a&#xD;
      laboratory in London. Tests will be done twice: after the first and second vaccine doses.&#xD;
&#xD;
      The study will help us understand if the body's immune response to the COVID-19 vaccine is&#xD;
      different in people with severe asthma who are on different treatments to manage their&#xD;
      symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measured immune response</measure>
    <time_frame>12 Months</time_frame>
    <description>To compare the measured immune response to vaccination in patients with 200 severe asthma and 50 healthy individuals. A positive response will be defined as IgG ≥0.201.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Range of immune responses</measure>
    <time_frame>12 Months</time_frame>
    <description>To evaluate the range of immune responses measured by IgG titres (very high: &gt;1.25, high: 0.751-1.25, medium: 0.401-0.75 or low: 0.201-0.4) in patients with 200 severe asthma and compare this with 50 healthy individuals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in responses between treatment groups</measure>
    <time_frame>12 Months</time_frame>
    <description>To identify any differences in responses between patients treated with biologics, standard inhaler treatment with/without maintenance oral corticosteroids (mOCS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between responses within the three biologics</measure>
    <time_frame>12 Months</time_frame>
    <description>To identify any differences between responses to vaccines amongst patient groups treated with three biologics (anti-IgE Omalizumab, anti-IL-5 Mepolizumab, and anti-IL-5receptor Benralizumab)</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Coronavirus Antibody Levels</condition>
  <arm_group>
    <arm_group_label>Asthma biologics</arm_group_label>
    <description>120 people receiving asthma biologics (monoclonal antibodies)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthma inhalers</arm_group_label>
    <description>40 people receiving asthma inhalers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid tablets</arm_group_label>
    <description>40 people needing daily steroid tablets to control their asthma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>50 age-matched healthy people</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not Interventional their treatments are their routine NHS care</intervention_name>
    <description>Not Interventional their treatments are their routine NHS care</description>
    <arm_group_label>Asthma biologics</arm_group_label>
    <arm_group_label>Asthma inhalers</arm_group_label>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>Steroid tablets</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will recruit patients that attended the severe asthma clinic. To recruit&#xD;
        age-matched controls we will randomly approach the patients and ask if their partners (or&#xD;
        age-matched family members or friends) would like to participate in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Age ≥ 16 years&#xD;
&#xD;
          2. For asthma patients:&#xD;
&#xD;
               1. Diagnosis of severe asthma (based on ATS/ERS consensus criteria)&#xD;
&#xD;
               2. Group A: Currently receiving an asthma biologic with treatment having started at&#xD;
                  least 3 months before first COVID-19 vaccine&#xD;
&#xD;
               3. Group B: on maintenance oral steroids at a dose of ≥5mg prednisolone (or&#xD;
                  equivalent) per day (at the time of first COVID-19 vaccine)&#xD;
&#xD;
               4. Group C: not on asthma biologic or maintenance oral steroids (at the time of&#xD;
                  vaccination) or stopped ≥3 months prior to first COVID-19 vaccine&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Current pregnancy or planning a pregnancy within the next 6 months&#xD;
&#xD;
          2. Current malignancy&#xD;
&#xD;
          3. Diagnosis of immunodeficiency requiring treatment&#xD;
&#xD;
          4. Additional exclusion criteria for asthma patients:&#xD;
&#xD;
               1. Group A: maintenance oral steroids at the time of first COVID-19 vaccine&#xD;
&#xD;
               2. Group B: on an asthma biologic at the time of first COVID-19 vaccine&#xD;
&#xD;
          5. Additional exclusion criteria for healthy controls cohort (as assessed by research&#xD;
             team):&#xD;
&#xD;
               1. No history of asthma or significant other lung disease&#xD;
&#xD;
               2. Severe chronic inflammatory disease&#xD;
&#xD;
               3. Severe cardiac disease&#xD;
&#xD;
               4. Diabetes&#xD;
&#xD;
          6. Previous proven COVID-19 infection&#xD;
&#xD;
          7. Inability to provide informed consent&#xD;
&#xD;
          8. Unwilling to have vaccination&#xD;
&#xD;
          9. Participation in another clinical trial involving an investigational medicinal product&#xD;
             (IMP).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hitasha Rupani</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Southampton NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Bower</last_name>
    <phone>02381204989</phone>
    <email>thomas.bower@uhs.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Bower</last_name>
      <phone>02381204989</phone>
      <email>thomas.bower@uhs.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Hitasha Rupani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Treeby</last_name>
      <phone>01392 403814</phone>
      <email>lisa.treeby@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Matthew Masoli</last_name>
      <email>matthew.masoli@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Masoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rekha Chaudhuri</last_name>
      <email>Rekha.Chaudhuri@ggc.scot.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Kayleigh Mckenna</last_name>
      <email>Kayleigh.McKenna@ggc.scot.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Rekha Chaudhuri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Trust Foundation</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gill Arbane</last_name>
      <email>Gill.Arbane@gstt.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Mathew Furtado</last_name>
      <email>Mathew.Furtado@gstt.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>David Jackson, MRCP MSc PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon Doe</last_name>
      <email>simon.doe@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Jamie Brown</last_name>
      <email>jamie.brown3@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Simon Doe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD000364. doi: 10.1002/14651858.CD000364.pub4. Review.</citation>
    <PMID>23450529</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

